Show simple item record

dc.contributor.authorSundaram, Kalyanen_US
dc.contributor.authorBardin, C. Wayneen_US
dc.contributor.authorBremner, William J.en_US
dc.contributor.authorCummings, David E.en_US
dc.contributor.authorKumar, Narenderen_US
dc.date.accessioned2008-10-17T20:42:18Z
dc.date.available2008-10-17T20:42:18Z
dc.date.issued1998-12en_US
dc.identifier.citationJ Clin Endocrinol Metab. 1998 Dec;83(12):4212-9en_US
dc.identifier.urihttp://hdl.handle.net/1773/4411
dc.description.abstract7alpha-Methyl-19-nortestosterone (MENT) is a potent synthetic androgen that cannot be converted to dihydrotestosterone. In this study we determined the relative androgenic, antigonadotropic, and anabolic potencies of testosterone vs. MENT in the nonhuman primate M. fascicularis. In castrated monkeys, dose-response relationships were generated for the effects of testosterone and MENT on gonadotropin levels, prostate growth, body weight, and lipid metabolism. In a pilot study, four monkeys were castrated, and magnetic resonance imaging (MRI) was used to document a 50% loss of prostate volume within 8 weeks, verifying that MRI is a reliable means to measure prostate size in this species. Two additional groups of six monkeys each were then castrated and serially administered four graded dosages of testosterone or MENT via osmotic minipumps over 20 weeks. Complete suppression of LH was achieved with a minimum of 0.3 mg/day MENT, compared to 3.0 mg/day testosterone. MENT supported body weight 10 times more potently than did testosterone. Baseline prostate volumes were maintained with 0.1-0.2 mg/day MENT vs. 0.3 mg/day testosterone. Thus, in monkeys, MENT is 10 times more potent than testosterone with regard to the clinically desirable end points of gonadotropin suppression and anabolism, but only twice as potent at stimulating prostate growth. These results suggest that MENT may have a wider therapeutic index than testosterone for human androgen replacement and male contraception.en_US
dc.language.isoen_USen_US
dc.publisherEndocrine Societyen_US
dc.subjectmale contraceptionen_US
dc.subjectandrologyen_US
dc.subjectgonadotropinsen_US
dc.subject5-alpha reductase inhibitorsen_US
dc.subjectspermatogenesisen_US
dc.subjecttestosteroneen_US
dc.subjectcolchicineen_US
dc.subjectklinefelter's syndromeen_US
dc.subjectreifenstein's syndromeen_US
dc.subject.meshBody Weight, drug effectsen_US
dc.subject.meshResearch Support, U.S. Gov't, Non-P.H.S.en_US
dc.subject.meshResearch Support, U.S. Gov't, P.H.S.en_US
dc.subject.meshAnimalsen_US
dc.subject.meshContraceptive Agents, Male, pharmacologyen_US
dc.subject.meshHormone Replacement Therapyen_US
dc.subject.meshComparative Studyen_US
dc.subject.meshMaleen_US
dc.subject.meshLuteinizing Hormone, antagonists & inhibitorsen_US
dc.subject.meshMacaca fascicularisen_US
dc.subject.meshOrchiectomyen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshAnabolic Agents, pharmacologyen_US
dc.subject.meshAndrogens, metabolismen_US
dc.subject.meshMagnetic Resonance Imagingen_US
dc.subject.meshTestosterone, pharmacology, therapeutic useen_US
dc.subject.meshResearch Support, Non-U.S. Gov'ten_US
dc.subject.meshProstate, anatomy & histology, drug effects, growth & developmenten_US
dc.subject.meshNandrolone, analogs & derivatives, pharmacologyen_US
dc.titleProstate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraceptionen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record